- Status:
- Red
- Decision Date:
- June 2022
Comments
RED:
NICE TA791 - Romosozumab for treating
severe osteoporosis. ICB commissioned. Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
search again
